In a cell line derived from CML (K562), co-treatment with ABT-737 circumvented the resistance to imatinib related to BCL-2 upregulation or loss of BIM or BAD [41]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.